文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA与GPRC5D双特异性抗体治疗浆细胞白血病的真实世界结局

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

这项多中心回顾性研究纳入122例原发性或继发性浆细胞白血病患者,评估BCMA和GPRC5D靶向双特异性抗体的真实世界疗效。总体缓解率55%,talquetamab方案生存优于teclistamab和elranatamab,活动性PCL预后更差。

要点

  • 总体缓解率55%,talquetamab线治疗61%、桥接CAR-T 58%、elranatamab 46%、teclistamab 33%。
  • talquetamab线治疗中位PFS 5.5个月、OS 11.5个月,桥接组两者均未达到。
  • 活动性PCL生存更差,talquetamab线治疗中位PFS/OS为6.9/12.2个月。

核心结论

  • 双特异性抗体在浆细胞白血病中耐受良好,talquetamab结局优于BCMA靶向双特异性抗体。

研究设计与样本

  • 多中心回顾性研究,纳入15个学术中心122例原发性或继发性浆细胞白血病患者。
  • 按双特异性抗体启动前30天内循环浆细胞≥5%分为活动性PCL,其余为历史性PCL。

主要发现

  • 细胞因子释放综合征1-2级占56%、3-4级占4%;神经毒性1-2级占16%、3-4级占5%。
  • 总体缓解率55%,talquetamab线治疗61%、桥接CAR-T 58%、elranatamab 46%、teclistamab 33%。
  • 中位随访8.3个月,talquetamab线治疗中位PFS 5.5个月、OS 11.5个月,桥接组两者均未达到。

临床怎么用

  • 在浆细胞白血病中可考虑使用双特异性抗体,talquetamab可能带来更优生存。
  • 活动性PCL患者预后较差,需更积极治疗策略。

局限性

  • 回顾性研究设计。
  • 样本量122例。
  • 中位随访8.3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell-redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as active (≥5% circulating plasma cells within 30 days before BsAb initiation) or historical. Patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging to CAR T-cell therapy (Tal Bridge, 11%). Cytokine release syndrome was grade 1 to 2 in 56% and grade 3 to 4 in 4% of patients, whereas neurotoxicity was grade 1 to 2 in 16% and grade 3 to 4 in 5% of patients. The overall response rate was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS values of 1.2 and 1.6 months and mOS values of 8.1 and 3.6 months, respectively (P = .007, P = .023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months vs 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P< .001, P = .002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were well tolerated in PCL, with talquetamab showing superior outcomes compared with B-cell maturation antigen-directed BsAbs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gaballa MR, Julian K, Afrough A, et al. Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia. Blood Adv. 2026. PMID: 42392158. doi:10.1182/bloodadvances.2026020826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。